ACUFREE is the 3rd-generation technological evolution of previous medical devices from the Tinnitech Group. The 2016-2023 period generated 5 development phases with evolving operating systems and related devices resulting in two biennial testing phases.
ACUFREE 3rd-generation: eight years of research & development
Il Dispositivo oggi contiene alti standard di elettronica, componentistica e specifiche tecniche.
Durante tutto questo percorso abbiamo negoziato al meglio per contenere i costi degli sviluppi software e hardware, in particolare in questi anni post-Covid di cambiamento e complessità della manifattura ed elettronica internazionale nei rapporti Europa-Asia (es. microchip e circuiti stampati).
Riteniamo doverose queste premesse per spiegare i costi e quindi il prezzo finale di ACUFREE.
Value and reasons for choosing ACUFREE
ACUFREE is a new method of treating Tinnitus which – although not guaranteeing results or effectiveness for all – is able to demonstrate, through the certified data of the 2022-23 clinical trials, quantitative and qualitative results favourable to our treatment for 7 out of 10 patients.
Quantitative factors: the 2022-23 Clinical Protocol delved into the condition of perceived discomfort of the 50 sufferers treated with 5 international methods of evaluation of Tinnitus: THI, TFI, VAS, SF-36 (quality of life) and Hearing Sensitivity.
All 5 measurements showed a trend and favourable data both in the short term (3 months) and in the long term (1 year). A quantitative performance that consolidates the possibilities of perceived efficacy for those who follow treatment with ACUFREE.
Results not achieved for everyone, but for a majority of the patients treated (7 out of 10).
Qualitative factors
Some peaks of improvement have already been reported for THI and TFI, both on averages and on individual cases. Reporting on the most difficult case, we found continued relief after 12 months of therapy:
- THI improved in 52% stable18% of patients (7 out of 10)
- THI with average value improved by 21,6%
- THI improved “from 10 to 0” in 3 out of 4 patients
- THI improved to “from 10 to 0” in 4 out of 5 patients among the 66% “positive” results
There are no other therapeutic solutions for Italian tinnitus patients which have obtained, after only 2 months of therapy, data and trends for clinical improvement comparable to these.
These results have been substantiated by 5 international evaluation standards, verified by official Ministry protocol agents and executed by a source of national medical excellence (the Tor Vergata General University hospital).